Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs

Not yet recruiting

• Conditions: Pancreatic Neuroendocine Neoplasms (pNETs)

• Registration Number: NCT07136701
• Lead Sponsor: Qilu Hospital of Shandong University

Brief Summary

The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).

The main questions it aims to answer are:

Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.

Participants will:

Provide retrospective clinical, pathological, and metabolic data from hospital records.

Have survival and recurrence outcomes assessed through follow-up data review.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-14
• Study First Submitted QC: 2025-08-21
• Last Update Submitted: 2025-08-21
• Study First Posted: 2025-08-22
• Last Update Posted: 2025-08-22
• Study Start: 2025-08-31
• Primary Completion: 2026-06-30
• Study Completion: 2027-07-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

Exclusion Criteria

• Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival	From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years

Secondary Outcome Measures

Name	Time	Method
Disease-specific survival	From date of diagnosis until death due to PanNETs, up to 12 years
Progression-free survival	From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.
Disease-free survival	From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.

Trial Locations

Locations (1)

Qilu Hospital of Shandong University; 🇨🇳 Jinan, Shandong, China